Identification

Name
Doxycycline
Accession Number
DB00254  (APRD00597)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

A synthetic tetracycline derivative with similar antimicrobial activity. Animal studies suggest that it may cause less tooth staining than other tetracyclines. It is used in some areas for the treatment of chloroquine-resistant falciparum malaria (malaria, falciparum).

Structure
Thumb
Synonyms
  • 5-hydroxy-α-6-deoxytetracycline
  • 6-alpha-deoxy-5-oxytetracycline
  • 6alpha-deoxy-5-oxytetracycline
  • 6α-deoxy-5-oxytetracycline
  • Anhydrous doxycycline
  • Doxiciclina
  • Doxycyclin
  • Doxycycline (anhydrous)
  • Doxycycline anhydrous
  • Doxycyclinum
Product Ingredients
IngredientUNIICASInChI Key
Doxycycline calcium8ZL07I20SB94088-85-4IYECPECUTCOMMD-QFWOMMJSSA-N
Doxycycline hyclate19XTS3T51U24390-14-5HALQELOKLVRWRI-VDBOFHIQSA-N
Doxycycline hydrochloride4182Z6T2ET10592-13-9RUYHIJHUVHIMIR-CVHRZJFOSA-N
Doxycycline monohydrateN12000U13O17086-28-1XQTWDDCIUJNLTR-CVHRZJFOSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ActiclateTablet, coated75 mg/1OralAqua Pharmaceuticals2014-07-28Not applicableUs
ActiclateTablet, coated150 mg/1OralAqua Pharmaceuticals2014-07-28Not applicableUs
Acticlate CAPCapsule75 mg/1OralAqua Pharmaceuticals2018-05-31Not applicableUs
Apprilon40 mgOralGalderma2012-11-29Not applicableCanada
AtridoxKitOralTolmar Inc1998-09-03Not applicableUs
Atridox8.8 %OralTolmar Inc2001-01-31Not applicableCanada
AtridoxKitOralDen Mat Holdings, Llc2016-12-01Not applicableUs
DoryxTablet, delayed release200 mg/1OralWarner Chilcott2013-07-012016-04-30Us00430 0114 20 nlmimage10 1a3a0d30
DoryxTablet, delayed release200 mg/1OralMayne Pharma2015-04-13Not applicableUs
DoryxTablet, delayed release50 mg/1OralMayne Pharma2015-05-26Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdoxaCapsule150 mg/1OralPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2011-06-01Not applicableUs10337 0815 06 nlmimage10 7203b95d
AlodoxTablet20 mg/1OralO Cu Soft, Inc.2008-10-01Not applicableUs
Alti-doxycycline - Tab 100mgTablet100 mgOralAltimed Pharma Inc.1995-12-312001-09-05Canada
Alti-doxycycline-cap 100mgCapsule100 mgOralAltimed Pharma Inc.1995-12-312001-09-05Canada
Apo-doxy Cap 100mgCapsule100 mgOralApotex Corporation1987-12-31Not applicableCanada
Apo-doxy Tabs 100mgTablet100 mgOralApotex Corporation1990-12-31Not applicableCanada
Dom-doxycyclineCapsule100 mgOralDominion Pharmacal2008-04-162016-10-25Canada
Dom-doxycyclineTablet100 mgOralDominion Pharmacal2008-04-162016-10-25Canada
Doxy 100Injection, powder, lyophilized, for solution100 mg/10mLIntravenousFresenius Kabi2000-10-17Not applicableUs
Doxy 100Injection, powder, lyophilized, for solution100 mg/10mLIntravenousGeneral Injectables & Vaccines2012-02-22Not applicableUs
International/Other Brands
Doxy (Galpharma) / Doxycin (Laboratoire Riva) / Doxylin (Actavis) / Jenacyclin / Microdox (Micro Labs) / NicAzelDoxyKit / Nu-Doxycycline (Nu-Pharm) / Supracyclin (Grünenthal) / Vibramycin (Pfizer)
Categories
UNII
334895S862
CAS number
564-25-0
Weight
Average: 444.4346
Monoisotopic: 444.153265754
Chemical Formula
C22H24N2O8
InChI Key
JBIWCJUYHHGXTC-AKNGSSGZSA-N
InChI
InChI=1S/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
IUPAC Name
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][C@@]12[C@@H](C)C3=C(C(O)=CC=C3)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])[C@H]2O

Pharmacology

Indication

Doxycycline is indicated for use in respiratory tract infections caused by Mycoplasma pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Legionella spp., or Klebsiella spp. It is also used for prophylaxis of malaria. Doxycycline is indicated for a variety of bacterial infections, from Mycobacterium fortuitum and M. marinum, to susceptible E. coli and Brucella spp. It can be used as an alternative to treating plague, tetanus, Campylobacter fetus

Associated Conditions
Pharmacodynamics

Doxycycline, a long-acting tetracycline derived from oxytetracycline, is used to inhibit bacterial protein synthesis and treat non-gonococcal urethritis and cervicitis, exacerbations of bronchitis in patients with COPD, and adult periodontitis.

Mechanism of action

Doxycycline, like minocycline, is lipophilic and can pass through the lipid bilayer of bacteria. Doxycycline reversibly binds to the 30 S ribosomal subunits and possibly the 50S ribosomal subunit(s), blocking the binding of aminoacyl tRNA to the mRNA and inhibiting bacterial protein synthesis. Doxycycline prevents the normal function of the apicoplast of Plasmodium falciparum, a malaria causing organism.

TargetActionsOrganism
A30S ribosomal protein S9
inhibitor
Escherichia coli (strain K12)
A30S ribosomal protein S4
inhibitor
Escherichia coli (strain K12)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
UProtein-arginine deiminase type-4Not AvailableHuman
UBeta-2-microglobulinNot AvailableHuman
Absorption

Completely absorbed following oral administration.

Volume of distribution
Not Available
Protein binding

>90%

Metabolism

Hepatic

Route of elimination

They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.

Half life

18-22 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include anorexia, nausea, diarrhoea, glossitis, dysphagia, enterocolitis and inflammatory lesions (with monilial overgrowth) in the anogenital region, skin reactions such as maculopapular and erythematous rashes, exfoliative dermatitis, photosensitivity, hypersensitivity reactions such as urticaria, angioneurotic oedema, anaphylaxis, anaphyl-actoid purpura, pericarditis, and exacerbation of systemic lupus erythematosus, benign intracranial hypertension in adults disappearing on discontinuation of the medicine, haematologic abnormalities such as haemolytic anaemia, thrombocytopenia, neutropenia, and eosinophilia. LD50=262 mg/kg (I.P. in rat).

Affected organisms
  • Enteric bacteria and other eubacteria
  • Treponema pallidum
  • Leptospira interrogans
  • Clostridium perfringens
  • Borrelia burgdorferi
  • Brucella abortus
  • Brucella canis
  • Chlamydia pneumoniae
  • Chlamydia trachomatis
  • Helicobacter pylori
  • Mycoplasma pneumoniae
  • Neisseria gonorrhoeae
  • Rickettsia rickettsii
  • Vibrio cholerae
  • Yersinia pestis
  • Chlamydia psittaci
Pathways
PathwayCategory
Doxycycline Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Doxycycline.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Doxycycline.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Doxycycline.Approved, Investigational
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Doxycycline.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Doxycycline.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Doxycycline.Approved
AcitretinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Acitretin.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Doxycycline is combined with Adapalene.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Doxycycline.Approved
AgmatineThe metabolism of Agmatine can be decreased when combined with Doxycycline.Experimental, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Doxycycline.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Doxycycline.Approved
AlcuroniumDoxycycline may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Doxycycline.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Doxycycline.Approved, Investigational
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Doxycycline.Approved, Vet Approved
AliskirenThe metabolism of Aliskiren can be decreased when combined with Doxycycline.Approved, Investigational
AlitretinoinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Alitretinoin.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Doxycycline.Approved
AlmasilateAlmasilate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Doxycycline.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Doxycycline.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Doxycycline.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Doxycycline.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Doxycycline.Approved, Illicit, Investigational
AluminiumAluminium can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Doxycycline.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Doxycycline.Approved, Investigational
AmdinocillinThe therapeutic efficacy of Amdinocillin can be decreased when used in combination with Doxycycline.Investigational, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Doxycycline.Approved, Investigational, Vet Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Doxycycline.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Doxycycline.Approved
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Doxycycline.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Doxycycline.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Doxycycline.Approved
AmobarbitalThe serum concentration of Doxycycline can be decreased when it is combined with Amobarbital.Approved, Illicit
AmoxicillinThe therapeutic efficacy of Amoxicillin can be decreased when used in combination with Doxycycline.Approved, Vet Approved
AmpicillinThe therapeutic efficacy of Ampicillin can be decreased when used in combination with Doxycycline.Approved, Vet Approved
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Doxycycline.Approved, Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Doxycycline.Approved, Investigational
ApalutamideThe metabolism of Apalutamide can be decreased when combined with Doxycycline.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Doxycycline.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Doxycycline.Approved, Investigational
AprepitantThe metabolism of Aprepitant can be decreased when combined with Doxycycline.Approved, Investigational
AranidipineThe metabolism of Aranidipine can be decreased when combined with Doxycycline.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Doxycycline.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Doxycycline.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Doxycycline is combined with Artemether.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Doxycycline.Approved
AspoxicillinThe therapeutic efficacy of Aspoxicillin can be decreased when used in combination with Doxycycline.Experimental
AstemizoleThe metabolism of Astemizole can be decreased when combined with Doxycycline.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Doxycycline.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Doxycycline.Approved, Investigational
AtorvastatinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Atorvastatin.Approved
AtracuriumDoxycycline may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateDoxycycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Doxycycline.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Doxycycline.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Doxycycline.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Doxycycline.Approved
AzelnidipineThe metabolism of Azelnidipine can be decreased when combined with Doxycycline.Approved, Investigational
AzidocillinThe therapeutic efficacy of Azidocillin can be decreased when used in combination with Doxycycline.Approved
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Doxycycline.Approved
AzlocillinThe therapeutic efficacy of Azlocillin can be decreased when used in combination with Doxycycline.Approved
BacampicillinThe therapeutic efficacy of Bacampicillin can be decreased when used in combination with Doxycycline.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Doxycycline.Investigational
BarbexacloneThe serum concentration of Doxycycline can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Doxycycline can be decreased when it is combined with Barbital.Illicit
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Doxycycline.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Doxycycline.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Doxycycline.Investigational
Beclomethasone dipropionateThe metabolism of Beclomethasone dipropionate can be decreased when combined with Doxycycline.Approved, Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Doxycycline.Approved
BencyclaneThe metabolism of Bencyclane can be decreased when combined with Doxycycline.Experimental
BenidipineThe metabolism of Benidipine can be decreased when combined with Doxycycline.Approved, Investigational
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Doxycycline.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Doxycycline.Approved
BenzylpenicillinThe therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Doxycycline.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Doxycycline.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Doxycycline.Approved, Withdrawn
BexaroteneThe risk or severity of adverse effects can be increased when Doxycycline is combined with Bexarotene.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Doxycycline.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Doxycycline.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Doxycycline.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Doxycycline.Approved, Experimental
Bismuth subcitrate potassiumThe serum concentration of Doxycycline can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth SubsalicylateThe serum concentration of Doxycycline can be decreased when it is combined with Bismuth Subsalicylate.Approved, Vet Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Doxycycline.Approved
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Doxycycline.Investigational
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Doxycycline.Approved, Investigational
BoceprevirThe metabolism of Boceprevir can be decreased when combined with Doxycycline.Approved, Withdrawn
BortezomibThe metabolism of Bortezomib can be decreased when combined with Doxycycline.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Doxycycline.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Doxycycline.Approved
Brentuximab vedotinThe metabolism of Brentuximab vedotin can be decreased when combined with Doxycycline.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Doxycycline.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Doxycycline.Approved, Investigational
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Doxycycline.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Doxycycline.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Doxycycline.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Doxycycline.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Doxycycline.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Doxycycline.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Doxycycline.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Doxycycline.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Doxycycline.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Doxycycline.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Doxycycline.Approved, Investigational
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Doxycycline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Doxycycline.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Doxycycline.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Doxycycline.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Doxycycline.Approved, Nutraceutical
Calcium AcetateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Chloride.Approved
Calcium CitrateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium levulinateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium levulinate.Approved, Experimental
Calcium pangamateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Doxycycline.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Doxycycline.Approved, Investigational
CarbamazepineThe serum concentration of Doxycycline can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbenicillinThe therapeutic efficacy of Carbenicillin can be decreased when used in combination with Doxycycline.Approved, Investigational
Carbenicillin indanylThe therapeutic efficacy of Carbenicillin indanyl can be decreased when used in combination with Doxycycline.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Doxycycline.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be decreased when combined with Doxycycline.Investigational
CarfecillinThe therapeutic efficacy of Carfecillin can be decreased when used in combination with Doxycycline.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Doxycycline.Approved, Investigational
CaroverineThe metabolism of Caroverine can be decreased when combined with Doxycycline.Experimental
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Doxycycline.Approved, Investigational
CaseinThe serum concentration of Doxycycline can be decreased when it is combined with Casein.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Doxycycline.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Doxycycline.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Doxycycline.Approved, Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Doxycycline.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Doxycycline.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Doxycycline.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Doxycycline.Approved, Illicit, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Doxycycline.Approved
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Doxycycline.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Doxycycline.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Doxycycline.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Doxycycline.Approved, Investigational
CilnidipineThe metabolism of Cilnidipine can be decreased when combined with Doxycycline.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Doxycycline.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Doxycycline.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Doxycycline.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
CisatracuriumDoxycycline may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Doxycycline.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Doxycycline.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Doxycycline.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Doxycycline.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Doxycycline.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Doxycycline.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Doxycycline.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Doxycycline.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Doxycycline.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Doxycycline.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Doxycycline.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Doxycycline.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Doxycycline.Approved, Illicit
ClorindioneDoxycycline may increase the anticoagulant activities of Clorindione.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Doxycycline.Approved, Illicit
CloxacillinThe therapeutic efficacy of Cloxacillin can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Doxycycline.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Doxycycline.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Doxycycline.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Doxycycline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Doxycycline.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Doxycycline.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Doxycycline.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Doxycycline.Approved, Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Doxycycline.Approved, Investigational
CrizotinibThe metabolism of Crizotinib can be decreased when combined with Doxycycline.Approved
CyclacillinThe therapeutic efficacy of Cyclacillin can be decreased when used in combination with Doxycycline.Approved
CyclandelateThe metabolism of Cyclandelate can be decreased when combined with Doxycycline.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Doxycycline.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Doxycycline.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
CytarabineThe metabolism of Cytarabine can be decreased when combined with Doxycycline.Approved, Investigational
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Doxycycline.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Doxycycline.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Doxycycline.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Doxycycline.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Doxycycline.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Doxycycline is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Doxycycline.Approved, Investigational
DarodipineThe metabolism of Darodipine can be decreased when combined with Doxycycline.Experimental
DarunavirThe metabolism of Darunavir can be decreased when combined with Doxycycline.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Doxycycline.Approved
DasatinibThe metabolism of Dasatinib can be decreased when combined with Doxycycline.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Doxycycline.Approved
DecamethoniumDoxycycline may increase the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Doxycycline.Approved, Investigational
DelamanidThe metabolism of Delamanid can be decreased when combined with Doxycycline.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Doxycycline.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Desvenlafaxine.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Doxycycline.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Doxycycline.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Doxycycline.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Doxycycline.Approved, Investigational
DexniguldipineThe metabolism of Dexniguldipine can be decreased when combined with Doxycycline.Experimental
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Doxycycline.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Doxycycline.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe metabolism of Dexverapamil can be decreased when combined with Doxycycline.Experimental
DiazepamThe metabolism of Diazepam can be decreased when combined with Doxycycline.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Doxycycline.Approved, Vet Approved
DicloxacillinThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
DicoumarolDoxycycline may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Doxycycline.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Doxycycline.Approved, Investigational
DigoxinThe metabolism of Digoxin can be decreased when combined with Doxycycline.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Doxycycline.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Doxycycline.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Doxycycline.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Doxycycline.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Doxycycline.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Doxycycline.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Doxycycline.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Doxycycline.Approved
DiphenadioneDoxycycline may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Doxycycline.Approved, Investigational
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Doxycycline.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Doxycycline.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Doxycycline.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Doxycycline.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Doxycycline.Approved, Investigational
Domoic AcidDoxycycline may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Doxycycline.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Doxycycline.Approved
DotarizineThe metabolism of Dotarizine can be decreased when combined with Doxycycline.Investigational
DoxacuriumDoxycycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe serum concentration of Doxycycline can be increased when it is combined with Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Doxycycline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Doxycycline.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Doxycycline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxycycline.Approved, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Doxycycline.Approved, Illicit
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Doxycycline.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Doxycycline.Approved, Investigational
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Doxycycline.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be decreased when combined with Doxycycline.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Doxycycline.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Doxycycline.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Doxycycline.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Doxycycline.Approved
EmopamilThe metabolism of Emopamil can be decreased when combined with Doxycycline.Experimental
EnalaprilThe metabolism of Enalapril can be decreased when combined with Doxycycline.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Doxycycline.Approved, Investigational
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Doxycycline.Approved
EperisoneThe metabolism of Eperisone can be decreased when combined with Doxycycline.Approved, Investigational
EpicillinThe therapeutic efficacy of Epicillin can be decreased when used in combination with Doxycycline.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Doxycycline.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Doxycycline.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Doxycycline.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Doxycycline.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Doxycycline.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Doxycycline.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Doxycycline.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Doxycycline.Approved, Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Doxycycline.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Doxycycline.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Doxycycline.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Doxycycline.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Doxycycline.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Doxycycline.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Doxycycline.Approved, Investigational
EthanolDoxycycline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Doxycycline.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Doxycycline.Approved
Ethyl biscoumacetateDoxycycline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Doxycycline.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Doxycycline.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxycycline.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Doxycycline.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Doxycycline.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Doxycycline.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Doxycycline.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Doxycycline.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Doxycycline.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Doxycycline.Approved, Investigational
FelbamateThe metabolism of Felbamate can be decreased when combined with Doxycycline.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Doxycycline.Approved, Investigational
FendilineThe metabolism of Fendiline can be decreased when combined with Doxycycline.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Doxycycline.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Doxycycline.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseDoxycycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateDoxycycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Doxycycline.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Doxycycline.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Doxycycline.Approved, Investigational
Fish oilThe metabolism of Fish oil can be decreased when combined with Doxycycline.Approved, Nutraceutical
FlibanserinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Flibanserin.Approved, Investigational
FlucloxacillinThe therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Doxycycline.Approved, Investigational
FluindioneDoxycycline may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Doxycycline.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Doxycycline.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Doxycycline.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Doxycycline.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Doxycycline.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Doxycycline.Approved, Illicit, Investigational
FluspirileneThe metabolism of Fluspirilene can be decreased when combined with Doxycycline.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Doxycycline.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Doxycycline.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Doxycycline.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Doxycycline.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fosamprenavir can be decreased when combined with Doxycycline.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Doxycycline.Approved
FosphenytoinThe serum concentration of Doxycycline can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Doxycycline.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Doxycycline.Approved, Investigational
GabapentinThe metabolism of Gabapentin can be decreased when combined with Doxycycline.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Doxycycline.Approved
GallamineDoxycycline may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideDoxycycline may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe metabolism of Gallopamil can be decreased when combined with Doxycycline.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Doxycycline.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Doxycycline.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Doxycycline.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Doxycycline.Approved
GlycerinThe serum concentration of Doxycycline can be increased when it is combined with Glycerin.Approved, Investigational
GranisetronThe metabolism of Granisetron can be decreased when combined with Doxycycline.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Doxycycline.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Doxycycline.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Doxycycline.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Doxycycline.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Doxycycline.Approved, Vet Approved
HexobarbitalThe serum concentration of Doxycycline can be decreased when it is combined with Hexobarbital.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Doxycycline.Approved, Investigational
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Doxycycline.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Doxycycline.Approved, Vet Approved
Hydrocortisone acetateThe metabolism of Hydrocortisone acetate can be decreased when combined with Doxycycline.Approved, Vet Approved
Hydrocortisone butyrateThe metabolism of Hydrocortisone butyrate can be decreased when combined with Doxycycline.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Doxycycline.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Doxycycline.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxycycline.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Doxycycline.Approved
IbuprofenThe serum concentration of Doxycycline can be increased when it is combined with Ibuprofen.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Doxycycline.Approved, Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Doxycycline resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Doxycycline.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Doxycycline.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Doxycycline.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Doxycycline.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Doxycycline.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Doxycycline.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Doxycycline.Approved
IndinavirThe metabolism of Indinavir can be decreased when combined with Doxycycline.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Doxycycline.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium can be decreased when combined with Doxycycline.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Doxycycline.Approved, Investigational
IronDoxycycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranDoxycycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateThe serum concentration of Doxycycline can be decreased when it is combined with Iron saccharate.Approved
IsavuconazoleThe metabolism of Isavuconazole can be decreased when combined with Doxycycline.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Doxycycline.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Doxycycline.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Doxycycline.Approved
IsotretinoinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Isotretinoin.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Doxycycline.Approved, Investigational
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Doxycycline.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Doxycycline.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Doxycycline.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Doxycycline.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Doxycycline.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Doxycycline.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Doxycycline.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Doxycycline.Approved, Investigational
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Doxycycline.Approved, Investigational
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Doxycycline.Approved, Investigational
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Doxycycline.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Doxycycline.Approved, Investigational
Lanthanum carbonateThe serum concentration of Doxycycline can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibThe metabolism of Lapatinib can be decreased when combined with Doxycycline.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Doxycycline.Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Doxycycline.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Doxycycline.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Doxycycline.Approved, Investigational
LevetiracetamThe metabolism of Levetiracetam can be decreased when combined with Doxycycline.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Doxycycline.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Doxycycline.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Doxycycline.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Doxycycline.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Doxycycline.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Doxycycline.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Doxycycline.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Doxycycline.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be decreased when combined with Doxycycline.Experimental
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Doxycycline.Approved, Investigational
LomerizineThe metabolism of Lomerizine can be decreased when combined with Doxycycline.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Doxycycline.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Doxycycline.Approved
LopinavirThe metabolism of Lopinavir can be decreased when combined with Doxycycline.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Doxycycline.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Doxycycline.Approved
LorpiprazoleThe metabolism of Lorpiprazole can be decreased when combined with Doxycycline.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Doxycycline.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Doxycycline.Approved, Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Doxycycline is combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Doxycycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Doxycycline.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Doxycycline.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Doxycycline.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Doxycycline is combined with Magnesium citrate.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateMagnesium salicylate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe therapeutic efficacy of Doxycycline can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Manidipine can be decreased when combined with Doxycycline.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Doxycycline.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Doxycycline.Approved, Vet Approved
MecamylamineDoxycycline may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Doxycycline.Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Doxycycline.Experimental, Investigational
MedrogestoneThe serum concentration of Medrogestone can be decreased when it is combined with Doxycycline.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Doxycycline.Approved, Investigational
MefloquineThe metabolism of Mefloquine can be decreased when combined with Doxycycline.Approved, Investigational
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Doxycycline.Approved, Vet Approved
MentholThe metabolism of Menthol can be decreased when combined with Doxycycline.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Doxycycline.Approved, Investigational
MetampicillinThe therapeutic efficacy of Metampicillin can be decreased when used in combination with Doxycycline.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Doxycycline.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Doxycycline.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Doxycycline.Illicit, Withdrawn
MethohexitalThe serum concentration of Doxycycline can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Doxycycline.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Doxycycline.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Doxycycline.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Doxycycline.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxycycline.Approved
MethylphenobarbitalThe serum concentration of Doxycycline can be decreased when it is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Doxycycline.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Doxycycline.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Doxycycline.Approved
MeticillinThe therapeutic efficacy of Meticillin can be decreased when used in combination with Doxycycline.Approved, Investigational
MetocurineDoxycycline may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideDoxycycline may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Doxycycline.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Doxycycline.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Doxycycline.Approved, Investigational
MezlocillinThe therapeutic efficacy of Mezlocillin can be decreased when used in combination with Doxycycline.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Doxycycline.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Doxycycline.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Doxycycline.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Doxycycline.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Doxycycline.Approved, Investigational
MifepristoneThe metabolism of Mifepristone can be decreased when combined with Doxycycline.Approved, Investigational
MipomersenDoxycycline may increase the hepatotoxic activities of Mipomersen.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Doxycycline.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Doxycycline.Approved
MivacuriumDoxycycline may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Doxycycline.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Doxycycline.Approved
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Doxycycline.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Doxycycline.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Doxycycline.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Doxycycline.Approved, Investigational
NafcillinThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Doxycycline.Approved, Investigational
NaftopidilThe metabolism of Naftopidil can be decreased when combined with Doxycycline.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Doxycycline.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Doxycycline.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Doxycycline.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Doxycycline.Approved, Withdrawn
NelfinavirThe metabolism of Nelfinavir can be decreased when combined with Doxycycline.Approved
NeomycinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinDoxycycline may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NeratinibThe metabolism of Neratinib can be decreased when combined with Doxycycline.Approved, Investigational
NevirapineThe metabolism of Nevirapine can be decreased when combined with Doxycycline.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Doxycycline.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Doxycycline.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Nicotine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Doxycycline.Approved
NiguldipineThe metabolism of Niguldipine can be decreased when combined with Doxycycline.Experimental
NilotinibThe metabolism of Nilotinib can be decreased when combined with Doxycycline.Approved, Investigational
NiludipineThe metabolism of Niludipine can be decreased when combined with Doxycycline.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Doxycycline.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Doxycycline.Approved, Investigational
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Doxycycline.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Doxycycline.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Doxycycline.Approved, Investigational
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Doxycycline.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Doxycycline.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Doxycycline.Approved
NylidrinThe metabolism of Nylidrin can be decreased when combined with Doxycycline.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Doxycycline.Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Doxycycline.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Doxycycline.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Doxycycline.Approved
OpiumThe metabolism of Opium can be decreased when combined with Doxycycline.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Doxycycline.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Doxycycline.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be decreased when combined with Doxycycline.Experimental, Investigational
OxacillinThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Doxycycline.Approved, Investigational
OxazepamThe metabolism of Oxazepam can be decreased when combined with Doxycycline.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Doxycycline.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Doxycycline is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Doxycycline.Approved, Vet Approved
PalbociclibThe metabolism of Palbociclib can be decreased when combined with Doxycycline.Approved, Investigational
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Doxycycline.Approved, Investigational
PancuroniumDoxycycline may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Doxycycline.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Doxycycline.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Doxycycline.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Doxycycline.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Doxycycline.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Doxycycline.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Doxycycline.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Doxycycline.Approved
PenamecillinThe therapeutic efficacy of Penamecillin can be decreased when used in combination with Doxycycline.Experimental
PenfluridolThe metabolism of Penfluridol can be decreased when combined with Doxycycline.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Doxycycline.Approved, Investigational
PentobarbitalThe serum concentration of Doxycycline can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Doxycycline.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Doxycycline.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Doxycycline.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Doxycycline.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Doxycycline.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Doxycycline.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Doxycycline.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Doxycycline.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Doxycycline.Withdrawn
PhenindioneDoxycycline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Doxycycline can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Doxycycline.Approved
PhenoxymethylpenicillinThe therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Doxycycline.Approved, Vet Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Doxycycline.Approved, Investigational
PhenytoinThe serum concentration of Doxycycline can be decreased when it is combined with Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Doxycycline.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Doxycycline.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Doxycycline.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Doxycycline.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Doxycycline.Approved
PinaveriumThe metabolism of Pinaverium can be decreased when combined with Doxycycline.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Doxycycline.Approved, Investigational
PipecuroniumDoxycycline may increase the neuromuscular blocking activities of Pipecuronium.Approved
PiperacillinThe therapeutic efficacy of Piperacillin can be decreased when used in combination with Doxycycline.Approved
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Doxycycline.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Doxycycline.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Doxycycline.Approved
PitolisantThe metabolism of Pitolisant can be decreased when combined with Doxycycline.Approved, Investigational
PivampicillinThe therapeutic efficacy of Pivampicillin can be decreased when used in combination with Doxycycline.Approved
PivmecillinamThe therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Doxycycline.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Doxycycline.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Doxycycline is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Doxycycline.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Doxycycline.Approved, Investigational
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
PramipexoleDoxycycline may increase the sedative activities of Pramipexole.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Doxycycline.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Doxycycline.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Doxycycline.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Doxycycline.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Doxycycline.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Doxycycline.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Doxycycline can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Doxycycline.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Doxycycline.Approved
PrimidoneThe serum concentration of Doxycycline can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe therapeutic efficacy of Procaine can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
Procaine benzylpenicillinThe therapeutic efficacy of Procaine benzylpenicillin can be decreased when used in combination with Doxycycline.Approved, Vet Approved
ProchlorperazineThe risk or severity of QTc prolongation can be increased when Doxycycline is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Doxycycline.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Doxycycline.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Doxycycline.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Doxycycline is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Doxycycline.Approved
PropericiazineThe serum concentration of Propericiazine can be increased when it is combined with Doxycycline.Approved, Investigational
PropicillinThe therapeutic efficacy of Propicillin can be decreased when used in combination with Doxycycline.Experimental
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Doxycycline.Vet Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Doxycycline.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Doxycycline.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Pseudoephedrine.Approved
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Doxycycline.Approved, Vet Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Doxycycline.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Doxycycline.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Doxycycline.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Doxycycline.Approved, Investigational
QuinaprilQuinapril can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Doxycycline.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Doxycycline.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Doxycycline.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Doxycycline.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Doxycycline.Approved, Investigational
RanitidineThe serum concentration of Doxycycline can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Doxycycline.Approved, Investigational
RapacuroniumDoxycycline may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Doxycycline.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Doxycycline.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Doxycycline.Approved, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Doxycycline.Approved
RifabutinThe metabolism of Rifabutin can be decreased when combined with Doxycycline.Approved, Investigational
RifampicinThe serum concentration of Doxycycline can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Doxycycline.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Doxycycline.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Doxycycline.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Doxycycline.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Doxycycline.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Doxycycline.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Doxycycline is combined with Rizatriptan.Approved
RocuroniumDoxycycline may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Doxycycline.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Doxycycline.Approved, Investigational
RopiniroleDoxycycline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Doxycycline.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Doxycycline.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Doxycycline.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Doxycycline.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Doxycycline.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Doxycycline.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Doxycycline.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Doxycycline.Approved, Investigational
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Doxycycline.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Doxycycline.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Doxycycline.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Doxycycline.Approved, Investigational
SecobarbitalThe serum concentration of Doxycycline can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be decreased when combined with Doxycycline.Investigational
SelexipagThe metabolism of Selexipag can be decreased when combined with Doxycycline.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Doxycycline.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Doxycycline.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Doxycycline.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Doxycycline.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Doxycycline.Approved, Investigational
SilodosinThe metabolism of Silodosin can be decreased when combined with Doxycycline.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Doxycycline.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Doxycycline.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Doxycycline.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Doxycycline.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Doxycycline.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Doxycycline.Approved, Investigational
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Doxycycline.Approved
Strontium ranelateThe serum concentration of Doxycycline can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SuccinylcholineDoxycycline may increase the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateSucralfate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Doxycycline.Approved, Investigational
SulbenicillinThe therapeutic efficacy of Sulbenicillin can be decreased when used in combination with Doxycycline.Experimental
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Doxycycline.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Doxycycline.Approved
SultamicillinThe therapeutic efficacy of Sultamicillin can be decreased when used in combination with Doxycycline.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Doxycycline is combined with Sumatriptan.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Doxycycline.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Doxycycline.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Doxycycline.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Doxycycline.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Doxycycline.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Doxycycline.Approved, Investigational
TalampicillinThe therapeutic efficacy of Talampicillin can be decreased when used in combination with Doxycycline.Experimental
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Doxycycline.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Doxycycline.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Doxycycline.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Doxycycline.Experimental
TazobactamThe therapeutic efficacy of Tazobactam can be decreased when used in combination with Doxycycline.Approved
Technetium Tc-99m oxidronateDoxycycline can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TelaprevirThe metabolism of Telaprevir can be decreased when combined with Doxycycline.Approved, Withdrawn
TelithromycinThe metabolism of Telithromycin can be decreased when combined with Doxycycline.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Doxycycline.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Doxycycline.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Doxycycline.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Doxycycline.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Doxycycline.Experimental
TerodilineThe metabolism of Terodiline can be decreased when combined with Doxycycline.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Doxycycline.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Doxycycline.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Doxycycline.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Doxycycline.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Doxycycline.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Doxycycline.Approved, Vet Approved
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be decreased when combined with Doxycycline.Investigational
TetrandrineThe metabolism of Tetrandrine can be decreased when combined with Doxycycline.Experimental
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Doxycycline.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Doxycycline.Approved
ThiamylalThe serum concentration of Doxycycline can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Doxycycline.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Doxycycline.Withdrawn
ThiopentalThe serum concentration of Doxycycline can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe serum concentration of Thioproperazine can be increased when it is combined with Doxycycline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Doxycycline.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Doxycycline.Approved, Investigational
TiagabineThe metabolism of Tiagabine can be decreased when combined with Doxycycline.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Doxycycline.Approved
TicarcillinThe therapeutic efficacy of Ticarcillin can be decreased when used in combination with Doxycycline.Approved, Investigational, Vet Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Doxycycline.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Doxycycline.Approved, Investigational
TioclomarolDoxycycline may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Doxycycline.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Doxycycline.Approved, Investigational
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Doxycycline.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Doxycycline.Approved, Investigational
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Doxycycline.Approved, Investigational
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be decreased when combined with Doxycycline.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Doxycycline.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Doxycycline.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Doxycycline.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Doxycycline.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Doxycycline.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Doxycycline.Approved, Investigational
TranilastThe metabolism of Tranilast can be decreased when combined with Doxycycline.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Doxycycline.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Doxycycline.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Doxycycline.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Doxycycline.Approved, Investigational
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Doxycycline.Approved, Investigational
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Doxycycline.Approved, Vet Approved
TrimebutineThe metabolism of Trimebutine can be decreased when combined with Doxycycline.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Doxycycline.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Doxycycline.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Doxycycline.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Doxycycline.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Doxycycline.Approved
TromethamineTromethamine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TubocurarineDoxycycline may increase the neuromuscular blocking activities of Tubocurarine.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Doxycycline.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Doxycycline.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Doxycycline.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Doxycycline.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Doxycycline is combined with Vancomycin.Approved
VandetanibThe metabolism of Vandetanib can be decreased when combined with Doxycycline.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Doxycycline.Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Doxycycline.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Doxycycline.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Doxycycline.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Doxycycline.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Doxycycline.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Doxycycline.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Doxycycline.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Doxycycline.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Doxycycline.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Doxycycline.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Doxycycline.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Doxycycline.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Doxycycline.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Doxycycline.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be decreased when combined with Doxycycline.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Doxycycline.Approved, Investigational
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Doxycycline.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Doxycycline.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Doxycycline.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Doxycycline.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be decreased when combined with Doxycycline.Experimental
YohimbineThe metabolism of Yohimbine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Doxycycline.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Doxycycline.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Doxycycline.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be decreased when combined with Doxycycline.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Doxycycline.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
Zinc acetateZinc acetate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc chlorideZinc chloride can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc oxideZinc oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Doxycycline.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Doxycycline is combined with Zolmitriptan.Approved, Investigational
ZolpidemDoxycycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Doxycycline.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Doxycycline.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Doxycycline.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Doxycycline.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Doxycycline.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take with a full glass of water Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.

References

Synthesis Reference

Dai-Wu Seol, "DNA cassette for the production of secretable recombinant trimeric TRAIL proteins, tetracycline/ doxycycline-inducible adeno-associated virus vector, their combination and use in gene therapy." U.S. Patent US20020128438, issued September 12, 2002.

US20020128438
General References
  1. Dahl EL, Shock JL, Shenai BR, Gut J, DeRisi JL, Rosenthal PJ: Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother. 2006 Sep;50(9):3124-31. [PubMed:16940111]
  2. Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, Pfarr KM, Adjei O, Buttner DW: Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol. 2003 Nov;192(4):211-6. Epub 2003 Mar 5. [PubMed:12684759]
  3. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf A: Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet. 2005 Jun 18-24;365(9477):2116-21. [PubMed:15964448]
External Links
Human Metabolome Database
HMDB0014399
KEGG Drug
D07876
KEGG Compound
C06973
PubChem Compound
54671203
PubChem Substance
46506491
ChemSpider
10469369
BindingDB
50041429
ChEBI
50845
ChEMBL
CHEMBL1433
Therapeutic Targets Database
DAP001371
PharmGKB
PA449415
HET
DXT
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Doxycycline
ATC Codes
A01AB22 — DoxycyclineJ01AA20 — Combinations of tetracyclinesJ01AA02 — Doxycycline
AHFS Codes
  • 08:12.24 — Tetracyclines
PDB Entries
2o7o / 2xrl / 5om2 / 5om3
FDA label
Download (48.1 KB)
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingPreventionSexually Transmitted Infections (STIs) / Syphilis1
0RecruitingTreatmentLymphoma, T-Cell, Cutaneous1
0RecruitingTreatmentMalignant Neoplasms of Respiratory and Intrathoracic Organs1
0RecruitingTreatmentOsteomyelitis1
1Active Not RecruitingPreventionCardiorenal Syndrome / Chronic Kidney Disease (CKD)1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableTo Determine Bioequivalence Under Fasting Conditions3
1CompletedBasic ScienceBacterial Infections / Healthy Volunteers / Infections, Fungal1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedOtherTo Determine Bioequivalence Under Fed Conditions2
1CompletedPreventionArteriovenous Malformations / Brain Aneurysms / Cavernous Angiomas1
1CompletedTreatmentAneurysms / Arteriovenous Malformations1
1RecruitingTreatmentMalignant Neoplasm of Breast / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract1
1TerminatedTreatmentAnthrax1
1, 2Active Not RecruitingHealth Services ResearchAcne Vulgaris1
1, 2CompletedTreatmentAmyloidosis; Heart (Manifestation) / Senile Cardiac Amyloidosis1
1, 2CompletedTreatmentAutoimmune Diseases / Endocrine System Diseases / Eye Diseases / Eye Diseases, Hereditary / Graves Diseases / Graves Ophthalmopathy / Hyperthyroidism / Immune System Diseases / Thyroid Diseases1
1, 2TerminatedTreatmentDiabetic Foot Ulcers (DFU)1
1, 2TerminatedTreatmentMelanoma1
1, 2Unknown StatusTreatmentAcne Vulgaris1
2Active Not RecruitingTreatmentAneurysms1
2Active Not RecruitingTreatmentMarginal Zone Lymphoma of Ocular Adnexal1
2Active Not RecruitingTreatmentPain1
2Active Not RecruitingTreatmentPeriodontitis, Chronic1
2Active Not RecruitingTreatmentPrimary Systemic Amyloidosis1
2CompletedNot AvailableEye Dryness1
2CompletedBasic ScienceAortic Aneurysm, Abdominal1
2CompletedPreventionCardiopulmonary Bypass / Coronary Artery Bypass Grafting (CABG) Surgery / Reperfusion Injury1
2CompletedPreventionCo-Infection / Mansonella Perstans Infection / Mycobacterium marinum infection / Tuberculosis1
2CompletedPreventionRas-wildtype Colorectal Cancer1
2CompletedPreventionRash Due to Epidermal Growth Factor Receptor Inhibitors1
2CompletedSupportive CareAdvanced Malignant Neoplasm / Dermatologic Complication / Dermatologic Complications / Neoplasms, Malignant1
2CompletedTreatmentAcne Vulgaris1
2CompletedTreatmentChronic Rhinosinusitis / Polyps, Nasal1
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentDiabetic Foot Ulcers (DFU)1
2CompletedTreatmentBacterial blepharitis / Eye Dryness / Meibomianitis1
2CompletedTreatmentLeft Ventricular Remodeling / Myocardial Infarction1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMansonella Perstans Infection / Mp Microfilaremia1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentPelvic Inflammatory Disease (PID)1
2CompletedTreatmentPeriodontal Diseases / Periodontitis1
2CompletedTreatmentPosterior Blepharitis1
2CompletedTreatmentRetinopathy, Diabetic2
2CompletedTreatmentProphylaxis of cardiomyopathy / Transthyretin Amyloidosis1
2CompletedTreatmentTuberculosis1
2CompletedTreatmentUrethritis1
2Not Yet RecruitingPreventionHeart Failure, Unspecified / ST Segment Elevation Myocardial Infarction (STEMI)1
2RecruitingTreatmentAneurysm, Coronary / Mucocutaneous Lymph Node Syndrome1
2RecruitingTreatmentAtopic Dermatitis (AD)1
2RecruitingTreatmentCarcinoma, Breast / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Uterine Corpus Cancer / Uterine Corpus Carcinosarcoma1
2RecruitingTreatmentChlamydophila Pneumoniae Infections / Coronary Heart Disease (CHD)1
2RecruitingTreatmentColorectal Cancers / Head and Neck Carcinoma1
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Mycosis Fungoides (MF) / Sezary Syndrome1
2RecruitingTreatmentHereditary Haemorrhagic Telangiectasia (HHT)1
2RecruitingTreatmentLarynx / LIP / Oral Cavity / Pharynx1
2RecruitingTreatmentMalignant Pleural Effusions1
2RecruitingTreatmentResectable Pancreatic Cancers1
2RecruitingTreatmentRosaceas1
2RecruitingTreatmentSeizures1
2RecruitingTreatmentSkin Toxicities1
2RecruitingTreatmentUlcerative Colitis (UC)1
2TerminatedTreatmentAdult Diffuse Large B-Cell Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Malignant Lymphoma - Lymphoplasmacytic / Marginal Zone B-Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas / Waldenström's Macroglobulinemia (WM)1
2TerminatedTreatmentMinor Intra-uterine Abnormalities1
2TerminatedTreatmentNon-ischaemic Cardiomyopathy / Systolic Heart Failure (NYHA II-III)1
2TerminatedTreatmentPolyp of Nasal Sinus1
2Unknown StatusPreventionMucositis1
2Unknown StatusTreatmentAcne1
2Unknown StatusTreatmentAutoimmune Diseases / Endocrine System Diseases / Eye Diseases / Eye Diseases, Hereditary / Graves Diseases / Graves Ophthalmopathy / Hyperthyroidism / Immune System Diseases / Thyroid Diseases1
2Unknown StatusTreatmentPlague1
2, 3Active Not RecruitingTreatmentAcute Myocardial Infarction (AMI) / Cardiovascular Disease (CVD) / Vascular Diseases1
2, 3CompletedNot AvailableJarisch Herxheimer Reaction / Relapsing Fever, Tick-Borne1
2, 3CompletedTreatmentDiabetes Mellitus With Periodontal Disease1
2, 3Not Yet RecruitingTreatmentCardiac AL Amyloidosis1
2, 3RecruitingTreatmentDry Macular Degeneration1
2, 3Unknown StatusTreatmentAcne / Inflammatory Reaction1
2, 3Unknown StatusTreatmentEye Burns1
3CompletedNot AvailableMycoplasma Infections / Persian Gulf Syndrome1
3CompletedDiagnosticLyme Neuroborreliosis1
3CompletedSupportive CareMetastatic Cancers1
3CompletedTreatmentAcne1
3CompletedTreatmentAlzheimer's Disease (AD)1
3CompletedTreatmentAndrogen Excess / Menstrual Irregularities / Polycystic Ovarian Syndrome (PCOS)1
3CompletedTreatmentChlamydial Infections1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentLyme Disease2
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPeriodontitis1
3CompletedTreatmentPeriodontitis, Chronic1
3CompletedTreatmentReactive Arthritis / Reiter's Disease1
3CompletedTreatmentRosaceas1
3CompletedTreatmentSevere Acne Vulgaris1
3CompletedTreatmentSyphilis1
3CompletedTreatmentUrethritis1
3CompletedTreatmentUrogential Chlamydia Trachomatis Infection1
3CompletedTreatmentUterine Hemorrhage1
3Enrolling by InvitationTreatmentNeuroborreliosis, Borrelia Burgdorferi1
3Not Yet RecruitingTreatmentFilariasis / Lymphatic Filariasis / Lymphedema of the extremities1
3RecruitingTreatmentAcne Vulgaris1
3RecruitingTreatmentCancers / Overall Survival / Quality of Life1
3RecruitingTreatmentESI-related Bleeding1
3RecruitingTreatmentFilariasis / Lymphatic Filariasis / Lymphedema of the extremities2
3RecruitingTreatmentIndigestion1
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentTTR Cardiac Amyloidosis1
3Unknown StatusNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
3Unknown StatusTreatmentAlzheimer's Disease (AD)1
3Unknown StatusTreatmentMetastatic Colorectal Cancers / Skin Toxicities1
3Unknown StatusTreatmentScrub Typhus1
4CompletedBasic ScienceBacterial Infections1
4CompletedPreventionPregnancy Termination / Vomiting1
4CompletedSupportive CareRosaceas1
4CompletedTreatmentAcne1
4CompletedTreatmentAcne Vulgaris3
4CompletedTreatmentBMI >30 kg/m2 / Type 2 Diabetes Mellitus1
4CompletedTreatmentBorrelia Infection / Lyme Disease1
4CompletedTreatmentBorreliosis / Early Lyme Disease / Erythema Chronicum Migrans / Lyme Disease1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCoxiella Infection / Fatigue Syndrome, Chronic / Q Fever1
4CompletedTreatmentCystic Fibrosis (CF)1
4CompletedTreatmentErythema Chronicum Migrans / Post-Lyme Disease Symptoms1
4CompletedTreatmentFilarial; Infestation1
4CompletedTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
4CompletedTreatmentOveractive Bladder1
4CompletedTreatmentPapulopustular Rosacea (PPR)2
4CompletedTreatmentPeriodontal Diseases / Type 2 Diabetes Mellitus1
4CompletedTreatmentRosaceas3
4CompletedTreatmentSinusitis1
4CompletedTreatmentBacterial blepharitis1
4Not Yet RecruitingTreatmentAnal infection / Chlamydia Trachomatis Infection / Vaginal Infections1
4RecruitingPreventionRabies1
4RecruitingTreatmentAcne1
4RecruitingTreatmentAnal chlamydia infection1
4RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
4RecruitingTreatmentDry Eye Syndromes / Meibomian Gland Dysfunction (MGD)1
4TerminatedTreatmentBladder Pain Syndrome / Chronic Pelvic Pain Syndrome (CPPS)1
4TerminatedTreatmentPeriodontitis1
4TerminatedTreatmentSeptic Abortion1
4Unknown StatusTreatmentCervicitis / Chlamydia Trachomatis / Genital Mycoplasma Infection / Urethritis1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD) / Inflammatory Reaction / Pulmonary Emphysema1
4Unknown StatusTreatmentEndometrial Bleeding / Periodontal Diseases1
4Unknown StatusTreatmentLyme Neuroborreliosis1
4WithdrawnPreventionCardiovascular Disease (CVD)1
4WithdrawnTreatmentPulmonary Disease, Chronic Obstructive1
Not AvailableActive Not RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Emphysema / Human Immunodeficiency Virus (HIV)1
Not AvailableActive Not RecruitingTreatmentRosaceas1
Not AvailableCompletedNot AvailableErythema Chronicum Migrans1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableLyme Neuroborreliosis1
Not AvailableCompletedNot AvailableMycoplasma Pneumoniae1
Not AvailableCompletedNot AvailablePeriodontal Diseases / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedBasic ScienceCognitive Dysfunctions / Paresis / Paresthesia / Radicular Pain / Tiredness1
Not AvailableCompletedPreventionFirst Trimester Abortion1
Not AvailableCompletedPreventionMethicillin Resistant Staphylococcus Aureus Skin Infections1
Not AvailableCompletedPreventionOsteoarthritis (OA)1
Not AvailableCompletedPreventionSyphilis1
Not AvailableCompletedTreatmentAcne Vulgaris / Diet Modification1
Not AvailableCompletedTreatmentAortic Aneurysms1
Not AvailableCompletedTreatmentCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentDiabetes Mellitus With Periodontal Disease1
Not AvailableCompletedTreatmentGastritis1
Not AvailableCompletedTreatmentOral Contraceptives (OC)1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableEnrolling by InvitationPreventionPropionibacterium1
Not AvailableNot Yet RecruitingTreatmentProsthetic Joint Infection1
Not AvailableRecruitingNot AvailableBullous Pemphigoid (BP)1
Not AvailableRecruitingPreventionMotility Disorders / Staphylococcus Aureus1
Not AvailableRecruitingTreatmentAmyloidosis; Systemic1
Not AvailableRecruitingTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA)1
Not AvailableRecruitingTreatmentMultiple Erythema Migrans1
Not AvailableRecruitingTreatmentPneumonia, Mycoplasma1
Not AvailableRecruitingTreatmentTick-borne Encephalitis (TBE)1
Not AvailableTerminatedTreatmentAdvanced Cancers / Malignant Pleural Effusions1
Not AvailableTerminatedTreatmentUlcerative Colitis (UC)1
Not AvailableUnknown StatusTreatmentBreakthrough Bleeding1
Not AvailableUnknown StatusTreatmentLateral Epicondylalgia (Tennis Elbow)1
Not AvailableUnknown StatusTreatmentScrub Typhus1
Not AvailableUnknown StatusTreatmentSuspected Early Lyme Neuroborreliosis1
Not AvailableWithdrawnPreventionSeroma1
Not AvailableWithdrawnSupportive CareLung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableWithdrawnTreatmentHeadache Disorders, Primary / Migraine Disorders / Migraine With Aura / Migraine Without Aura / Migraines / Migrainous Headache1
Not AvailableWithdrawnTreatmentRotator Cuff Injury1

Pharmacoeconomics

Manufacturers
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Watson laboratories inc
  • Watson pharmaceuticals inc
  • Galderma laboratories lp
  • Rachelle laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pfizer laboratories div pfizer inc
  • Lannett holdings inc
  • Mutual pharmaceutical co inc
  • Pliva inc
  • Mayne pharma international faulding pharm
  • Warner chilcott bermuda ltd
  • Medicis pharmaceutical corp
  • Halsey drug co inc
  • Heather drug co inc
  • Interpharm inc
  • Private formulations inc
  • Ranbaxy pharmaceuticals inc
  • Superpharm corp
  • Warner chilcott div warner lambert co
  • West ward pharmaceutical corp
  • Teva pharmaceuticals usa inc
  • Collagenex inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Tolmar inc
  • Corepharma llc
  • Larken laboratories inc
  • Mutual pharmacal co
  • Truxton inc
  • Vintage pharmaceuticals inc
Packagers
  • Actavis Group
  • Acura Pharmaceutical Technologies Inc.
  • Advanced Pharmaceutical Services Inc.
  • Advanced Vision Research
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apace Packaging
  • Apical Pharmaceutical Corporation
  • Apotheca Inc.
  • Apothecon
  • APP Pharmaceuticals
  • Aqua Pharmaceuticals
  • A-S Medication Solutions LLC
  • Avidas Pharmaceuticals
  • Bedford Labs
  • Belgomex Sprl
  • Ben Venue Laboratories Inc.
  • Bioglan Pharmaceuticals Co.
  • Blenheim Pharmacal
  • Block Drug Corp.
  • Blu Pharmaceuticals LLC
  • Bryant Ranch Prepack
  • Bv Pharbita
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Catalent Pharma Solutions
  • Collagenex Pharmaceuticals Inc.
  • Community Action Inc. Community Health Services
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • Darby Dental Supply Co. Inc.
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DSM Corp.
  • Eon Labs
  • Galderma Laboratories
  • Golden State Medical Supply Inc.
  • Goldline Laboratories Inc.
  • H and H Laboratories
  • H.J. Harkins Co. Inc.
  • Hikma Pharmaceuticals
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Lannett Co. Inc.
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mayne Pharma International Pty Ltd.
  • Mckesson Corp.
  • Medisca Inc.
  • Medvantx Inc.
  • Mississippi State Dept Health
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Oclassen Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patheon Inc.
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Manufacturing Research Services Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmaderm
  • Pharmedix
  • Pharmpak Inc.
  • Physicians Total Care Inc.
  • Pliva Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar Inc.
  • Tya Pharmaceuticals
  • Universal Laboratories Inc.
  • Veratex Corp.
  • Versapharm Inc.
  • Warner Chilcott Co. Inc.
  • Watson Pharmaceuticals
  • WC Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral20 mg/1
KitOral
Tablet, delayed releaseOral200 mg/1
Capsule, extended releaseOral100 mg
Tablet, delayed releaseOral120 mg/1
Tablet, delayed releaseOral60 mg/1
TabletOral100 mg
CapsuleOral150 mg/1
CapsuleOral40 mg/1
CapsuleOral75 mg/1
For suspensionOral25 mg/5mL
Injection, powder, lyophilized, for solutionIntravenous100 mg/100mg
Injection, powder, lyophilized, for solutionIntravenous100 mg/10mL
Injection, powder, lyophilized, for solutionIntravenous200 mg/20mL
Powder, for suspensionOral25 mg/5mL
TabletOral150 mg/1
TabletOral50 mg/1
TabletOral75 mg/1
Tablet, coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
CapsuleOral100 mg/1
CapsuleOral50 mg/1
Capsule, gelatin coatedOral100 mg/1
Capsule, gelatin coatedOral50 mg/1
TabletOral100 mg/1
Tablet, coatedOral150 mg/1
Tablet, coatedOral75 mg/1
Tablet, delayed releaseOral100 mg/1
Tablet, delayed releaseOral50 mg/1
Tablet, delayed releaseOral75 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral75 mg/1
Tablet, delayed releaseOral150 mg/1
CapsuleOral50 mg/50mg
CapsuleOral100 mg/100mg
Kit
Capsule, delayed release pelletsOral40 mg/1
CapsuleOral20 mg
CapsuleOral100 mg
SyrupOral50 mg/5mL
PowderIntravenous100 mg
Prices
Unit descriptionCostUnit
Vibramycin 25 mg/5ml Suspension 60ml Bottle36.29USD bottle
Adoxa pak 1-150 mg tablet19.93USD tablet
Doryx 150 mg Enteric Coated Tabs17.51USD tab
Doryx dr 150 mg tablet16.83USD tablet
Doxycycline hyc 100 mg vial14.16USD vial
Adoxa 100 mg tablet13.86USD tablet
Monodox 100 mg capsule13.46USD capsule
Adoxa 75 mg tablet12.77USD tablet
Oracea 40 mg Delayed Release Capsule12.44USD capsule
Oracea 40 mg capsule11.96USD capsule
Avidoxy 100 mg tablet11.52USD tablet
Monodox 75 mg capsule11.02USD capsule
Doryx 100 mg Enteric Coated Tabs10.31USD tab
Doryx dr 100 mg tablet9.91USD tablet
Adoxa pak 1-100 mg tablet9.88USD tablet
Doxycycline Monohydrate 150 mg tablet9.51USD tablet
Adoxa 50 mg tablet9.29USD tablet
Doxycycline mono 150 mg tablet9.13USD tablet
Doryx 75 mg Enteric Coated Tabs8.76USD tab
Doryx dr 75 mg tablet8.42USD tablet
Vibramycin 100 mg capsule6.67USD capsule
Vibra-tabs 100 mg tablet6.67USD tablet
Monodox 50 mg capsule6.0USD capsule
Doxycycline mono 100 mg tablet5.98USD tablet
Periostat 20 mg tablet5.75USD tablet
Doxycycline mono 75 mg tablet5.74USD tablet
Doxycycline Monohydrate 100 mg tablet5.12USD tablet
Doxycycline mono 50 mg tablet4.17USD tablet
Doxycycline Monohydrate 50 mg tablet3.0USD tablet
Doxycycline hyclate powder2.56USD g
Vibramycin 50 mg capsule2.41USD capsule
Doxycycline Monohydrate 100 mg capsule2.22USD capsule
Vibramycin 100 mg Capsule1.91USD capsule
Doxycycline Monohydrate 50 mg capsule1.51USD capsule
Doxycycline hyclate 100 mg tablet1.28USD tablet
Doxycycline hyclate 20 mg tablet1.28USD tablet
Doxycycline Hyclate 100 mg capsule1.18USD capsule
Doxycycline Hyclate 50 mg capsule0.76USD capsule
Vibramycin 50 mg/5ml Syrup0.67USD ml
Vibramycin 50 mg/5 ml syrup0.64USD ml
Apo-Doxy 100 mg Capsule0.61USD capsule
Apo-Doxy 100 mg Tablet0.61USD tablet
Doxycin 100 mg Capsule0.61USD capsule
Doxycin 100 mg Tablet0.61USD tablet
Novo-Doxylin 100 mg Capsule0.61USD capsule
Novo-Doxylin 100 mg Tablet0.61USD tablet
Nu-Doxycycline 100 mg Capsule0.61USD capsule
Pms-Doxycycline 100 mg Capsule0.61USD capsule
Pms-Doxycycline 100 mg Tablet0.61USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6958161No2002-12-152022-12-15Us
US8715724No2008-02-032028-02-03Us
US7211267No2002-04-052022-04-05Us
US7232572No2002-04-052022-04-05Us
US7749532No2007-12-192027-12-19Us
US8206740No2005-12-242025-12-24Us
US8394405No2004-04-072024-04-07Us
US8394406No2004-04-072024-04-07Us
US8470364No2004-04-072024-04-07Us
US8603506No2002-04-052022-04-05Us
US5789395No1996-08-302016-08-30Us
US5919775No1996-08-302016-08-30Us
US8709478No2004-04-072024-04-07Us
US9241946No2002-04-052022-04-05Us
US9511031No2014-10-232034-10-23Us
US9446057No2014-12-232034-12-23Us
US9295652No2014-10-232034-10-23Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)201 °CNot Available
water solubility630 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.02SANGSTER (1994)
logS-2.87ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.63 mg/mLALOGPS
logP-0.72ALOGPS
logP-3.3ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)2.93ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area181.62 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity113.89 m3·mol-1ChemAxon
Polarizability43.65 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.85
Blood Brain Barrier-0.9881
Caco-2 permeable-0.8706
P-glycoprotein substrateSubstrate0.699
P-glycoprotein inhibitor INon-inhibitor0.8038
P-glycoprotein inhibitor IINon-inhibitor0.8628
Renal organic cation transporterNon-inhibitor0.9562
CYP450 2C9 substrateNon-substrate0.8008
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6551
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9144
CYP450 2D6 inhibitorNon-inhibitor0.9293
CYP450 2C19 inhibitorNon-inhibitor0.9099
CYP450 3A4 inhibitorNon-inhibitor0.8567
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8086
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8632
BiodegradationNot ready biodegradable0.9941
Rat acute toxicity2.3159 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9946
hERG inhibition (predictor II)Non-inhibitor0.7466
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Tetracyclines
Sub Class
Not Available
Direct Parent
Tetracyclines
Alternative Parents
Naphthacenes / Anthracenecarboxylic acids and derivatives / Tetralins / Aryl ketones / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Aralkylamines / Cyclohexenones / Tertiary alcohols / Vinylogous acids
show 9 more
Substituents
Tetracycline / Naphthacene / Tetracene / Anthracene carboxylic acid or derivatives / Tetralin / Aryl ketone / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Cyclohexenone / Aralkylamine
show 24 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
tetracyclines (CHEBI:50845) / Linear tetracyclines (C06973) / Linear tetracyclines (LMPK07000001)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.
Gene Name
rpsI
Uniprot ID
P0A7X3
Uniprot Name
30S ribosomal protein S9
Molecular Weight
14856.105 Da
References
  1. Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. doi: 10.1152/ajpcell.00047.2010. Epub 2010 Jun 30. [PubMed:20592239]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Translation repressor activity, nucleic acid binding
Specific Function
One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in trans...
Gene Name
rpsD
Uniprot ID
P0A7V8
Uniprot Name
30S ribosomal protein S4
Molecular Weight
23468.915 Da
References
  1. Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. doi: 10.1152/ajpcell.00047.2010. Epub 2010 Jun 30. [PubMed:20592239]
3. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Pringle M, Fellstrom C, Johansson KE: Decreased susceptibility to doxycycline associated with a 16S rRNA gene mutation in Brachyspira hyodysenteriae. Vet Microbiol. 2007 Jul 20;123(1-3):245-8. Epub 2007 Feb 25. [PubMed:17428623]
  2. Kumar S, Kutlin A, Roblin P, Kohlhoff S, Bodetti T, Timms P, Hammerschlag MR: Isolation and antimicrobial susceptibilities of Chlamydial isolates from Western barred bandicoots. J Clin Microbiol. 2007 Feb;45(2):392-4. Epub 2006 Nov 22. [PubMed:17122017]
  3. Ross JI, Eady EA, Cove JH, Cunliffe WJ: 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother. 1998 Jul;42(7):1702-5. [PubMed:9661007]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein-arginine deiminase activity
Specific Function
Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance. Citrullinates histone...
Gene Name
PADI4
Uniprot ID
Q9UM07
Uniprot Name
Protein-arginine deiminase type-4
Molecular Weight
74078.65 Da
References
  1. Knuckley B, Luo Y, Thompson PR: Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008 Jan 15;16(2):739-45. Epub 2007 Oct 13. [PubMed:17964793]
Details
5. Beta-2-microglobulin
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Identical protein binding
Specific Function
Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
Gene Name
B2M
Uniprot ID
P61769
Uniprot Name
Beta-2-microglobulin
Molecular Weight
13714.43 Da
References
  1. Giorgetti S, Raimondi S, Pagano K, Relini A, Bucciantini M, Corazza A, Fogolari F, Codutti L, Salmona M, Mangione P, Colombo L, De Luigi A, Porcari R, Gliozzi A, Stefani M, Esposito G, Bellotti V, Stoppini M: Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem. 2011 Jan 21;286(3):2121-31. doi: 10.1074/jbc.M110.178376. Epub 2010 Nov 10. [PubMed:21068391]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Zhao XJ, Ishizaki T: A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8. [PubMed:10716067]
  3. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:18